[1] Jennekens FG, Kater L. The central nervous system in systemic lupus erythematosus. Part 2. Pathogenetic mechanisms of clinical syndromes: a literature investigation[J]. Rheumatology (Oxford), 2002,41(6):619-630. DOI: 10.1093/rheumatology/41.6.619.
[2] Lønnebakken MT, Gerdts E. Libman-Sacks endocarditis and cerebral embolization in antiphospholipid syndrome[J]. Eur J Echocardiogr, 2008,9(1):192-193. DOI: 10.1093/ejechocard/jem067.
[3] Fox IS, Spence AM, Wheelis RF, et al. Cerebral embolism in Libman-Sacks endocarditis[J]. Neurology, 1980,30(5):487-491. DOI: 10.1212/wnl.30.5.487.
[4] Kato T, Takama N, Harada T, et al. Nonbacterial thrombotic endocarditis-a rare case of acute libman-sacks endocarditis complicated by multiple cerebral infarcts: case report and literature review[J]. CASE (Phila), 2020,4(6):507-511. DOI: 10.1016/j.case. 2020.09.005.
[5] Jedliński I, Duszyńska M, Lehmann-Kopydłowska A, et al. Nawracajacy wieloogniskowy udar mózgu w przebiegu zapalenia wsierdzia Libmana-Sacksa u młodej kobiety z toczniem rumieniowatym układowym [Recurrent multi-focal cerebral stroke complicating Libman-Sacks endocarditis in a young woman with systemic lupus erythromatosus][J]. Kardiol Pol, 2009,67(1):50-52.
[6] Roldan CA, Sibbitt WL, Qualls CR, et al. Libman-Sacks endocarditis and embolic cerebrovascular disease[J]. JACC Cardiovasc Imaging, 2013,6(9):973-983. DOI: 10.1016/j.jcmg.2013.04.012.
[7] Ide S, Kakeda S, Miyata M, et al. Intracranial vessel wall lesions in patients with systematic lupus erythematosus[J]. J Magn Reson Imaging, 2018,48(5):1237-1246. DOI: 10.1002/jmri.25966.
[8] Takeshita S, Ogata T, Tsugawa J, et al. Isolated cerebral vasculitis in the unilateral middle cerebral artery in a case with SLE[J]. Intern Med, 2020,59(24):3225-3227. DOI: 10.2169/internalmedicine.4958-20.
[9] Kato R, Sumitomo S, Kawahata K, et al. Successful treatment of cerebral large vessel vasculitis in systemic lupus erythematosus with intravenous pulse cyclophosphamide[J]. Lupus, 2015,24(8):880-884. DOI: 10.1177/0961203315570163.
[10] 张辉,杨念生,鲁静,等. 狼疮肾炎诊疗规范[J]. 中华内科杂志,2021,60(9):784-790. DOI:10.3760/cma.j.cn112138- 20210609-00410.
[11] 赵久良,沈海丽,柴克霞,等. 抗磷脂综合征诊疗规范[J]. 中华内科杂志,2022,61(9):1000-1007. DOI:10.3760/cma.j.cn112138-20211222-00907.
[12] Mishima S, Kaneko K, Okazaki Y, et al. A woman with systemic lupus erythematosus, multiple pregnancy complications, and cerebral infarction who was only positive for phosphatidylserine-dependent antiprothrombin antibodies [J]. Mod Rheumatol Case Rep, 2021,5(1):47-51. DOI: 10.1080/24725625.2020.1782030.
[13] Sciascia S, Sanna G, Murru V, et al. Anti-prothrombin (aPT) and anti-phosphatidylserine/prothrombin (aPS/PT) antibodies and the risk of thrombosis in the antiphospholipid syndrome. A systematic review[J]. Thromb Haemost, 2014,111(2):354-364. DOI: 10.1160/TH13-06-0509.
[14] Vlagea A, Gil A, Cuesta MV, et al. Antiphosphatidylserine/prothrombin antibodies (aPS/PT) as potential markers of antiphospholipid syndrome[J]. Clin Appl Thromb Hemost, 2013,19(3):289-296. DOI: 10.1177/1076029612437578.
[15] Shi H, Zheng H, Yin YF, et al. Antiphosphatidylserine/prothrombin antibodies (aPS/PT) as potential diagnostic markers and risk predictors of venous thrombosis and obstetric complications in antiphospholipid syndrome[J]. Clin Chem Lab Med, 2018,56(4):614-624. DOI: 10.1515/cclm-2017-0502.
[16] Pontara E, Cattini MG, Cheng C, et al. Insight into the hypercoagulable state of high-risk thrombotic APS patients: contribution of aβ2GPI and aPS/PT antibodies[J]. J Thromb Haemost, 2021,19(3):805-813. DOI: 10.1111/jth.15199.
[17] Nojima J, Iwatani Y, Suehisa E, et al. The presence of anti-phosphatidylserine/prothrombin antibodies as risk factor for both arterial and venous thrombosis in patients with systemic lupus erythematosus[J]. Haematologica, 2006,91(5):699-702.
[18] Li S, Bai Y, Meng J, et al. Prevalence and diagnostic value of non-criteria antiphospholipid antibodies for antiphospholipid syndrome in Chinese patients[J]. Front Immunol, 2023,14:1107510. DOI: 10.3389/fimmu. 2023.1107510.
[19] 中华医学会血液学分会血栓与止血学组. 易栓症诊断与防治中国指南(2021年版)[J]. 中华血液学杂志,2021,42(11):881-888. DOI:10.3760/cma.j.issn.0253-2727.2021. 11.001.
[20] Afeltra A, Vadacca M, Conti L, et al. Thrombosis in systemic lupus erythematosus: congenital and acquired risk factors[J]. Arthritis Rheum, 2005,53(3):452-459. DOI: 10.1002/art.21172.
[21] Monzón Manzano E, Fernández-Bello I, Justo Sanz R, et al. Insights into the procoagulant profile of patients with systemic lupus erythematosus without antiphospholipid antibodies[J]. J Clin Med, 2020,9(10):3297. DOI: 10.3390/jcm9103297.
[22] Brouwer JL, Bijl M, Veeger NJ, et al. The contribution of inherited and acquired thrombophilic defects, alone or combined with antiphospholipid antibodies, to venous and arterial thromboembolism in patients with systemic lupus erythematosus[J]. Blood, 2004,104(1):143-148. DOI: 10.1182/blood-2003-11-4085.
[23] Vayá A, Santaolaria M, Micó L, et al. Thrombotic events in systemic lupus erythematosus. Its association with acquired and inherited thrombophilic defects[J]. Clin Hemorheol Microcirc, 2008,40(2):79-87.
|